Marshall Wace, LLP Rallybio Corp Call Options Transaction History
Marshall Wace, LLP
- $63.3 Billion
- Q1 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding RLYB
# of Institutions
64Shares Held
30.7MCall Options Held
0Put Options Held
0-
Viking Global Investors LP4.19MShares$5.03 Million0.03% of portfolio
-
5 Am Venture Management, LLC San Francisco, CA3.63MShares$4.36 Million2.37% of portfolio
-
New Leaf Venture Partners, L.L.C. New York, NY3.3MShares$3.96 Million5.35% of portfolio
-
Tpg Gp A, LLC Fort Worth, TX3.03MShares$3.63 Million0.12% of portfolio
-
Pivotal Bio Venture Partners Investment Advisor LLC San Francisco, CA2.4MShares$2.89 Million3.26% of portfolio
About Rallybio Corp
- Ticker RLYB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 32,132,000
- Market Cap $38.6M
- Description
- Rallybio Corporation, a clinical-stage biotechnology company, engages in discovering, developing, manufacturing, and delivering therapies that enhance the lives of patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that is in Phase I clinical trial for the prevention of feta...